DK1250138T3 - Fulvestrantformulering - Google Patents

Fulvestrantformulering

Info

Publication number
DK1250138T3
DK1250138T3 DK01900186T DK01900186T DK1250138T3 DK 1250138 T3 DK1250138 T3 DK 1250138T3 DK 01900186 T DK01900186 T DK 01900186T DK 01900186 T DK01900186 T DK 01900186T DK 1250138 T3 DK1250138 T3 DK 1250138T3
Authority
DK
Denmark
Prior art keywords
fulvestrant formulation
fulvestrant
formulation
Prior art date
Application number
DK01900186T
Other languages
English (en)
Other versions
DK1250138T4 (da
Inventor
John Raymond Evans
Rosalind Ursula Grundy
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26243352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1250138(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1250138T3 publication Critical patent/DK1250138T3/da
Publication of DK1250138T4 publication Critical patent/DK1250138T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
DK01900186.6T 2000-01-10 2001-01-08 Fulvestrantformulering DK1250138T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0000313.7A GB0000313D0 (en) 2000-01-10 2000-01-10 Formulation
GBGB0008837.7A GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
PCT/GB2001/000049 WO2001051056A1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation

Publications (2)

Publication Number Publication Date
DK1250138T3 true DK1250138T3 (da) 2006-01-23
DK1250138T4 DK1250138T4 (da) 2015-07-27

Family

ID=26243352

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10180667.7T DK2266573T3 (da) 2000-01-10 2001-01-08 Fulvestrantformulering
DK01900186.6T DK1250138T4 (da) 2000-01-10 2001-01-08 Fulvestrantformulering

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10180667.7T DK2266573T3 (da) 2000-01-10 2001-01-08 Fulvestrantformulering

Country Status (41)

Country Link
US (5) US20030125387A1 (da)
EP (4) EP1250138B2 (da)
JP (3) JP3713237B2 (da)
KR (1) KR100802366B1 (da)
CN (1) CN1222292C (da)
AR (1) AR027510A1 (da)
AT (1) ATE306928T1 (da)
AU (1) AU762080B2 (da)
BE (1) BE1013477A3 (da)
BG (1) BG65776B1 (da)
BR (1) BR0107445B1 (da)
CA (1) CA2351004C (da)
CH (1) CH696260A5 (da)
CO (1) CO5280206A1 (da)
CY (1) CY1116520T1 (da)
CZ (1) CZ304689B6 (da)
DE (2) DE60114145T3 (da)
DK (2) DK2266573T3 (da)
EE (1) EE05421B1 (da)
EG (1) EG24074A (da)
ES (3) ES2543384T3 (da)
FR (1) FR2803516B1 (da)
GB (3) GB0000313D0 (da)
HK (3) HK1049286B (da)
HU (1) HU230162B1 (da)
IL (2) IL150230A0 (da)
IS (1) IS2932B (da)
IT (2) ITTO20010005A1 (da)
MX (1) MXPA02006698A (da)
MY (1) MY118583A (da)
NL (1) NL1017075C2 (da)
NO (2) NO336286B1 (da)
PL (1) PL202525B1 (da)
PT (2) PT2266573E (da)
RU (1) RU2263507C9 (da)
SI (2) SI2266573T1 (da)
SK (1) SK287221B6 (da)
TW (1) TWI259086B (da)
UA (1) UA75879C2 (da)
WO (1) WO2001051056A1 (da)
ZA (1) ZA200204165B (da)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
RU2004102393A (ru) * 2001-07-07 2005-03-27 Астразенека Аб (Se) Фармацевтическая композиция для внутримышечного введения фульвестранта
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
WO2003100008A2 (en) 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
CA2604393A1 (en) * 2005-04-15 2006-10-26 Schering Corporation Methods and compositions for treating or preventing cancer
US20090227552A1 (en) * 2005-09-26 2009-09-10 Kellie Ann Hooley Fulvestrant formulations
US9180088B2 (en) 2008-03-07 2015-11-10 Scidose, Llc Fulvestrant formulations
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
CA2800673A1 (en) 2010-06-10 2011-12-15 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
BR112013006331B1 (pt) 2010-09-16 2021-09-21 Shimoda Biotech (Pty) Ltd Formulação compreendendo fulvestranto e ciclodextrina e seu uso
EP2711010B1 (en) 2011-05-20 2018-10-31 Capital, Business Y Gestión De Finanzas, S.L Pharmaceutical composition
CN102391341B (zh) * 2011-08-09 2013-05-22 福建省微生物研究所 制备6,7-脱氢-17β-烃酰氧基诺龙的方法
CN103070871B (zh) * 2011-10-26 2015-04-15 正大天晴药业集团股份有限公司 一种氟维司群的药物组合物
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9187460B2 (en) 2011-12-14 2015-11-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
MX2014007198A (es) 2011-12-16 2014-10-13 Olema Pharmaceuticals Inc Compuestos novedosos de benzopirano, composiciones y usos de los mismos.
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
EP2836199A1 (en) * 2012-04-09 2015-02-18 Scidose LLC Fulvestrant formulations
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2013386732B2 (en) 2013-04-18 2018-10-18 Xi'an Libang Pharmaceutical Technology Co., Ltd. Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof
US10392667B2 (en) 2013-06-07 2019-08-27 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
WO2015033302A2 (en) * 2013-09-06 2015-03-12 Salah Uddin Ahmed Fulvestrant compositions
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
MA39741A (fr) 2014-03-13 2017-01-18 Hoffmann La Roche Combinaisons thérapeutiques avec des modulateurs du récepteur des œstrogènes
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
CN112457310A (zh) 2014-12-18 2021-03-09 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
HUE055321T2 (hu) 2015-10-01 2021-11-29 Olema Pharmaceuticals Inc Tetrahidro-1H-pirido[3,4-b]indol anti-ösztrogén hatóanyagok
CA3001526A1 (en) 2015-10-13 2017-04-20 Themis Medicare Limited Fulvestrant compositions
US10118910B2 (en) 2015-12-09 2018-11-06 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
WO2017175810A1 (ja) * 2016-04-06 2017-10-12 富士フイルム株式会社 医薬組成物
WO2017174757A1 (en) 2016-04-08 2017-10-12 F. Hoffmann-La Roche Ag Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
MX2018013414A (es) * 2016-05-06 2019-06-06 Eagle Pharmaceuticals Inc Formulaciones de fulvestrant y metodos para su uso.
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
EP3466430B1 (en) * 2016-05-31 2020-04-29 FUJIFILM Corporation Pharmaceutical composition
EP3472159A1 (en) 2016-06-16 2019-04-24 F. Hoffmann-La Roche AG TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
WO2017216279A1 (en) * 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag Heteroaryl estrogen receptor modulators and uses thereof
CN107789320B (zh) * 2016-08-31 2021-06-22 鲁南制药集团股份有限公司 一种氟维司群缓释注射液及其制备工艺
AU2018329202B2 (en) 2017-09-11 2022-10-27 Atossa Therapeutics, Inc. Methods for making and using endoxifen
IL274433B1 (en) * 2017-11-08 2024-03-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of using them
JP2021503478A (ja) 2017-11-16 2021-02-12 ノバルティス アーゲー 組み合わせ治療
WO2019151353A1 (ja) * 2018-01-31 2019-08-08 富士フイルム株式会社 注射用製剤の製造方法
RU2684330C1 (ru) * 2018-02-02 2019-04-08 Закрытое Акционерное Общество "Биокад" Композиции фулвестранта
CA3101421A1 (en) 2018-05-24 2019-11-28 Kashiv Biosciences, Llc Prodrugs of fulvestrant
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN111035613A (zh) * 2018-10-12 2020-04-21 江苏恒瑞医药股份有限公司 一种包含氟维司群的可注射的药物组合物及其制备方法
CA3118330A1 (en) 2018-11-01 2020-05-07 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EA202192019A1 (ru) 2019-02-15 2021-11-02 Новартис Аг Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
JP2022532918A (ja) 2019-05-20 2022-07-20 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
RU2722988C1 (ru) * 2019-11-19 2020-06-05 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей
CN113260353A (zh) * 2019-12-11 2021-08-13 上海博志研新药物技术有限公司 氟维司群药物组合物、其制备方法及应用
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
JP2023553808A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
EP4251648A2 (en) 2020-11-24 2023-10-04 Novartis AG Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
WO2022169780A1 (en) 2021-02-02 2022-08-11 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
KR20230094172A (ko) * 2021-12-20 2023-06-27 주식회사 삼양홀딩스 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB817241A (en) 1957-08-21 1959-07-29 Vismara Francesco Spa Oily solutions for parenteral administration containing adreno-cortical hormones
FR6241E (fr) 1905-04-19 1906-10-10 Ktiengesellschaft Système de refroidissement du piston des moteurs à explosions et des compresseurs
DE947335C (de) 1954-10-19 1956-08-16 Schering Ag Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron
US2983649A (en) 1957-10-15 1961-05-09 Francesco Vismara Societa Per Ricinoleic acid ester solutions of adreno-cortical hormones
GB1060632A (en) * 1962-09-11 1967-03-08 Olin Mathieson Steroid compositions
US3164520A (en) * 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
JPS4327327Y1 (da) 1965-01-07 1968-11-12
NL151903B (nl) 1965-03-24 1977-01-17 Schering Ag Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
USRE28690E (en) * 1965-05-05 1976-01-20 Schering Aktiengesellschaft 17α-Ethinyl-18-methyl-19-nortestosterone esters
GB1207571A (en) * 1967-01-13 1970-10-07 Takeda Chemical Industries Ltd Injectable composition
SU549118A1 (ru) 1973-04-02 1977-03-05 Способ синхронизации половой охоты у циклирующих свиноматок
SU676284A1 (ru) 1975-06-26 1979-07-30 Научно-Исследовательский Институт Животноводства Способ синхронизации половой охоты у самок домашних животных
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
US4048309A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid ointment formulations
NL7711916A (nl) * 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
EP0310542B1 (de) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE3733478A1 (de) 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
JPH04327327A (ja) 1991-04-25 1992-11-16 Toyoda Gosei Co Ltd スリーブとホースの加締め用ダイス
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
US20010006963A1 (en) 1995-03-16 2001-07-05 Ursula Lachnit-Fixson Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
DE19510861A1 (de) 1995-03-16 1996-09-19 Schering Ag Einmonatsspritze als Depot-Kontrazeptivum und für die Hormonersatztherapie für peri- und praemenopausale Frauen
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
JPH09208496A (ja) * 1996-01-30 1997-08-12 Takeda Chem Ind Ltd Ｌｈ−ｒｈ拮抗物質含有組成物
DE19613972A1 (de) 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US5952338A (en) 1996-07-05 1999-09-14 Takeda Chemical Industries, Ltd. Agent for prophylaxis and treatment of disturbance of visual function
JPH10203982A (ja) * 1996-07-05 1998-08-04 Takeda Chem Ind Ltd 視機能障害の予防・治療剤
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19638045A1 (de) 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
JPH10152438A (ja) * 1996-11-22 1998-06-09 Takeda Chem Ind Ltd １−アザキサントン誘導体またはその塩の安定化方法および１−アザキサントン誘導体含有組成物
JPH11158200A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd ヒト成長ホルモン・亜鉛複合体及びその用途
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
WO1999027906A1 (en) 1997-12-03 1999-06-10 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated castor oil
ES2524141T3 (es) 1999-04-01 2014-12-04 Talon Therapeutics, Inc. Composiciones para tratar el cáncer
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
JP4327327B2 (ja) 2000-04-03 2009-09-09 ロボテック株式会社 固定スプレー揺動装置
RU2004102393A (ru) 2001-07-07 2005-03-27 Астразенека Аб (Se) Фармацевтическая композиция для внутримышечного введения фульвестранта
GB0912999D0 (en) 2009-07-27 2009-09-02 Astrazeneca Ab Method-803

Also Published As

Publication number Publication date
PL202525B1 (pl) 2009-07-31
HK1052884B (zh) 2006-07-14
ES2248272T3 (es) 2006-03-16
BR0107445A (pt) 2002-09-17
GB2359254A (en) 2001-08-22
CZ304689B6 (cs) 2014-09-03
SI1250138T1 (sl) 2006-02-28
US20100152149A1 (en) 2010-06-17
EG24074A (en) 2008-05-11
HUP0204137A2 (hu) 2003-04-28
CH696260A5 (de) 2007-03-15
EP1250138B1 (en) 2005-10-19
NO337329B1 (no) 2016-03-14
EP1669073A2 (en) 2006-06-14
JP2004107353A (ja) 2004-04-08
NL1017075A1 (nl) 2001-07-11
GB2359254B (en) 2002-06-19
PT102548A (pt) 2001-07-31
NO336286B1 (no) 2015-07-13
HUP0204137A3 (en) 2005-03-29
US7456160B2 (en) 2008-11-25
NO20023227L (no) 2002-07-03
HK1049286B (zh) 2006-04-07
BG65776B1 (bg) 2009-11-30
DE10100779A1 (de) 2001-07-26
SK287221B6 (sk) 2010-03-08
GB0000313D0 (en) 2000-03-01
PT2266573E (pt) 2015-07-28
RU2263507C9 (ru) 2020-03-18
ITTO20010005A0 (it) 2001-01-09
ITTO20010008A0 (it) 2001-01-10
JP2011190275A (ja) 2011-09-29
EE200200387A (et) 2003-10-15
IS6454A (is) 2002-07-03
EP2266573B1 (en) 2015-06-17
HU230162B1 (hu) 2015-09-28
ITTO20010008A1 (it) 2002-07-10
EP2286818B1 (en) 2020-03-18
MY118583A (en) 2004-12-31
ES2186517B2 (es) 2004-03-16
US8466139B2 (en) 2013-06-18
NO20150741L (no) 2002-07-03
DK1250138T4 (da) 2015-07-27
UA75879C2 (en) 2006-06-15
BR0107445B1 (pt) 2012-10-30
BG106833A (en) 2003-03-31
AR027510A1 (es) 2003-04-02
AU762080B2 (en) 2003-06-19
ES2186517A1 (es) 2003-05-01
DE60114145D1 (de) 2006-03-02
AU2386301A (en) 2001-07-24
RU2263507C2 (ru) 2005-11-10
KR100802366B1 (ko) 2008-02-13
CZ20022384A3 (cs) 2002-09-11
CN1394141A (zh) 2003-01-29
ATE306928T1 (de) 2005-11-15
DK2266573T3 (da) 2015-07-20
CY1116520T1 (el) 2017-03-15
DE60114145T2 (de) 2006-07-13
BE1013477A3 (fr) 2002-02-05
US20010020016A1 (en) 2001-09-06
EP1669073A3 (en) 2008-03-19
RU2002121507A (ru) 2004-03-20
SK9842002A3 (en) 2003-05-02
EE05421B1 (et) 2011-06-15
US20120329766A1 (en) 2012-12-27
MXPA02006698A (es) 2002-09-30
WO2001051056A1 (en) 2001-07-19
HK1150021A1 (en) 2011-10-28
EP2286818A1 (en) 2011-02-23
CN1222292C (zh) 2005-10-12
JP2003519659A (ja) 2003-06-24
IL150230A0 (en) 2002-12-01
ZA200204165B (en) 2003-10-29
CA2351004A1 (en) 2001-07-10
ITTO20010005A1 (it) 2001-07-11
KR20020073499A (ko) 2002-09-26
IS2932B (is) 2015-12-15
EP2266573A1 (en) 2010-12-29
CA2351004C (en) 2003-02-18
SI1250138T2 (sl) 2015-09-30
NL1017075C2 (nl) 2001-09-25
ES2543384T3 (es) 2015-08-18
EP1250138B2 (en) 2015-07-08
HK1049286A1 (en) 2003-05-09
DE60114145T3 (de) 2015-09-17
PL356030A1 (en) 2004-06-14
HK1052884A1 (en) 2003-10-03
GB0008837D0 (en) 2000-05-31
FR2803516A1 (fr) 2001-07-13
US8329680B2 (en) 2012-12-11
ES2248272T5 (es) 2015-08-19
SI2266573T1 (sl) 2015-08-31
US20030125387A1 (en) 2003-07-03
TWI259086B (en) 2006-08-01
US20050043285A1 (en) 2005-02-24
CO5280206A1 (es) 2003-05-30
US6774122B2 (en) 2004-08-10
NO20023227D0 (no) 2002-07-03
GB0100407D0 (en) 2001-02-21
JP3713237B2 (ja) 2005-11-09
EP1250138A1 (en) 2002-10-23
IL150230A (en) 2006-10-31
FR2803516B1 (fr) 2003-03-28

Similar Documents

Publication Publication Date Title
DE60114145D1 (de) Fulvestrant formulierung
ATE303787T1 (de) Schergelzusammensetzungen
AR028197A1 (es) Composiciones antitranspirantes
NO20031869D0 (no) Antiinflammatoriske midler
DE50114386D1 (de) Ng
DE60044147D1 (de) Knetvorrichtung
DE60107598D1 (de) Smart-skin strukturen
ATE263487T1 (de) Flüssige formulierungen
NO20030917D0 (no) Anvendelse
ATE369830T1 (de) Schweisshemmende zusammensetzungen
ATE314049T1 (de) Schweisshemmende zusammensetzungen
DE60116858D1 (de) Zusammensetzung
DE60122834D1 (de) Torsions-Kipp-Komponente
ATE270044T1 (de) Fungizide formulierung
ATE268116T1 (de) Mesotrion-formulierungen
DE50105875D1 (de) Bauteil
DE60107312D1 (de) Feste Zusammensetzung
DE50107699D1 (de) Bauelement
ATA12432000A (de) Bauelement
SE9902902D0 (sv) New formulation
UA4611S (uk) Сервірувальний набір
DK1341539T3 (da) Antiinflammatoriske midler
SE9903391D0 (sv) Novel formulation
FI20000584A0 (fi) Teline
SE0100199D0 (sv) New formulation